10:41 AM EDT, 06/17/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said the US Food and Drug Administration granted an orphan drug designation to its Deramiocel therapy candidate to treat Becker Muscular Dystrophy, a neuromuscular disorder.

The biologics license application for Deramiocel to treat Duchenne Muscular Dystrophy remains under priority review with a target action date of Aug. 31, the company said Tuesday in a statement.

Capricor plans to advance "a fully integrated platform targeting the cardiac and skeletal complications of muscular dystrophy," according to the statement.

The company's shares fell 2.7% in recent trading Tuesday.

Price: 12.05, Change: -0.33, Percent Change: -2.67